Font Size: Increase Font Size Decrease Font Size Restart Font Size   English Website    Sitio en Espanol

Contact us
Why us?
Why Costa Rica?


Lucentis is an antibody derived from Avastin, specifically designed for use in the eye. It is a smaller molecule than Avastin and binds to VEGF-A. It is the only currently approved (by the FDA) angiogenesis inhibitor for the treatment of Wet Age-Related Macular Degeneration. Results from large phase III clinical trials ANCHOR and MARINA showed that 90% of Lucentis-treated patients stabilized vision and 40% improved vision by 3 lines on the chart. Monthly injections are required for 3 months, and further injections may be needed depending on response. Like Avastin, and because of the risk of thrombo-embolic events, we do not recommend a Lucentis injection if you have had a heart attack or a stroke in the last 12 months. No systemic side-effects have been reported with Lucentis.

AMD    Intravitreal Injections



San Josť, Costa Rica, CIMA Hospital, Tower 3, Office 221